Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders

Reka Brubel, Attila Bokor, Akos Pohl, Gabriella Krisztina Schilli, Laszlo Szereday, Reka Bacher-Szamuel, Janos Rigo, Beata Polgar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders. Design Prospective case-control study. Setting University medical centers. Patient(s) A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. Intervention(s) Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women. Main Outcome Measure(s) The expression of mRNA and serum concentration of Gal-9. Result(s) Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I–II) and moderate-severe (III–IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels. Conclusion(s) Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders.

Original languageEnglish
Pages (from-to)1016-1025.e2
JournalFertility and Sterility
Volume108
Issue number6
DOIs
Publication statusPublished - Dec 2017

Keywords

  • ELISA
  • Endometriosis
  • biomarker
  • galectin-9
  • serum

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders'. Together they form a unique fingerprint.

  • Cite this